Procter & Gamble Health Ltd
Procter & Gamble Health Ltd Share Price Today: Live Updates & Key Insights
Get insights on Procter & Gamble Health Ltd’s fundamentals, financials, shareholding, peer comparison, corporate actions & performance. Track key metrics, price trends & market sentiment for informed decisions. Explore all data at Motilal Oswal.
Procter & Gamble Health Ltd Share Price Chart
Procter & Gamble Health Ltd Fundamentals
Traded Volume: 5,214
Market Cap(Cr): 9,678
Avg Traded Price 5837.73
1 Year return 13.89%
Upper Circuit 5,900
Lower Circuit 5,800.5
P/E TTM 32.00
P/B Ratio 185.00
Traded Value(Cr) 304.00
EPS TTM 184.826
Book value 184.826
Dividend 3.00%
Procter & Gamble Health Ltd Share Price Performance
Shows the percentage change in stock price over different time periods
This section highlights Procter & Gamble Health Ltd stock price performance across key timeframes, including 1-week, 1-month, 3-month, Year-To-Date (YTD), and 1-year returns. It provides insights into the Procter & Gamble Health Ltd share price history, short-term movements, long-term trends, and overall investor sentiment
1W -0.41%
1M -5.12%
3M -7.24%
1Y +13.89%
YTD +13.15%
Procter & Gamble Health Ltd Traded Volume Movement
Shows the trading volume over different time periods
This section highlights Procter & Gamble Health Ltd daily and average traded volumes, offering insights into investor activity and market liquidity. Higher volumes than average often indicate rising interest, news impact, or shifting market sentiment
Yesterday 5360.00
Day Before Yesterday 8193.00
1W Avg 7548.60
1M Avg 9167.76
3M Avg 11302.68
Procter & Gamble Health Ltd Technical Details
Procter & Gamble Health Ltd technical indicators, such as support and resistance levels and pivot points, are calculated based on historical price and volume trends. These metrics help traders anticipate possible price movements and make informed trading decisions.
Support 1 5787
Support 2 5744
Support 3 5688
Pivot Point : 5844
Resistance 1 5887
Resistance 2 5943
Resistance 3 5986
Procter & Gamble Health Ltd Corporate Actions
Procter & Gamble Health Ltd corporate actions include dividends, bonus issues, stock splits, and key company updates that may affect share price and investor sentiment. This section provides timely details on past and upcoming actions, including ex-date, record date, and payout ratio - helping investors make informed decisions based on Procter & Gamble Health Ltd’s capital allocation strategies.
All
Ex-Date 22-Aug-2025 Type D Description 45.00/share@450.00% Record Date 22-Aug-2025 Ratio 450.00
Ex-Date 21-Feb-2025 Type D Description 80.00/share@800.00% Record Date 21-Feb-2025 Ratio 800.00
Ex-Date 28-Nov-2024 Type D Description 60.00/share@600.00% Record Date - Ratio 600.00
Ex-Date 14-Feb-2024 Type D Description 50.00/share@500.00% Record Date 14-Feb-2024 Ratio 500.00
Ex-Date 14-Feb-2024 Type D Description 150.00/share@1500.00% Record Date 14-Feb-2024 Ratio 1500.00
Ex-Date 23-Nov-2023 Type D Description 50.00/share@500.00% Record Date - Ratio 500.00
Ex-Date 13-Feb-2023 Type D Description 45.00/share@450.00% Record Date 13-Feb-2023 Ratio 450.00
Ex-Date 15-Nov-2022 Type D Description 11.50/share@115.00% Record Date - Ratio 115.00
Ex-Date 12-May-2022 Type D Description 41.00/share@410.00% Record Date 13-May-2022 Ratio 410.00
Ex-Date 02-Nov-2021 Type D Description 90.00/share@900.00% Record Date - Ratio 900.00
Ex-Date 02-Nov-2021 Type D Description 40.00/share@400.00% Record Date - Ratio 400.00
Ex-Date 18-Nov-2020 Type D Description 188.00/share@1880.00% Record Date - Ratio 1880.00
Ex-Date 18-Nov-2020 Type D Description 42.00/share@420.00% Record Date - Ratio 420.00
Ex-Date 23-May-2019 Type D Description 416.00/share@4160.00% Record Date - Ratio 4160.00
Ex-Date 23-May-2019 Type D Description 24.00/share@240.00% Record Date - Ratio 240.00
Ex-Date 21-May-2018 Type D Description 15.00/share@150.00% Record Date - Ratio 150.00
Ex-Date 25-May-2017 Type D Description 11.00/share@110.00% Record Date - Ratio 110.00
Ex-Date 22-Apr-2016 Type D Description 7.50/share@75.00% Record Date - Ratio 75.00
Ex-Date 30-Mar-2015 Type D Description 6.00/share@60.00% Record Date - Ratio 60.00
Ex-Date 10-Mar-2014 Type D Description 8.50/share@85.00% Record Date - Ratio 85.00
Ex-Date 07-Mar-2013 Type D Description 2.50/share@25.00% Record Date - Ratio 25.00
Ex-Date 22-Oct-2010 Type D Description 95.00/share@950.00% Record Date 25-Oct-2010 Ratio 950.00
Ex-Date 18-Mar-2010 Type D Description 20.00/share@200.00% Record Date - Ratio 200.00
Ex-Date 06-Apr-2009 Type D Description 17.50/share@175.00% Record Date - Ratio 175.00
Ex-Date 04-Apr-2008 Type D Description 10.00/share@100.00% Record Date - Ratio 100.00
Ex-Date 21-Mar-2007 Type D Description 10.00/share@100.00% Record Date - Ratio 100.00
Ex-Date 21-Mar-2007 Type D Description 20.00/share@200.00% Record Date - Ratio 200.00
Dividends
Announcement Date 22-Aug-2025 Ex Dividend Date 22-Aug-2025 Dividend(%) 450
Announcement Date 21-Feb-2025 Ex Dividend Date 21-Feb-2025 Dividend(%) 800
Announcement Date 28-Nov-2024 Ex Dividend Date 28-Nov-2024 Dividend(%) 600
Announcement Date 14-Feb-2024 Ex Dividend Date 14-Feb-2024 Dividend(%) 500
Announcement Date 14-Feb-2024 Ex Dividend Date 14-Feb-2024 Dividend(%) 1500
Announcement Date 23-Nov-2023 Ex Dividend Date 23-Nov-2023 Dividend(%) 500
Announcement Date 13-Feb-2023 Ex Dividend Date 13-Feb-2023 Dividend(%) 450
Announcement Date 15-Nov-2022 Ex Dividend Date 15-Nov-2022 Dividend(%) 115
Announcement Date 12-May-2022 Ex Dividend Date 12-May-2022 Dividend(%) 410
Announcement Date 02-Nov-2021 Ex Dividend Date 02-Nov-2021 Dividend(%) 900
Announcement Date 02-Nov-2021 Ex Dividend Date 02-Nov-2021 Dividend(%) 400
Announcement Date 18-Nov-2020 Ex Dividend Date 18-Nov-2020 Dividend(%) 1880
Announcement Date 18-Nov-2020 Ex Dividend Date 18-Nov-2020 Dividend(%) 420
Announcement Date 23-May-2019 Ex Dividend Date 23-May-2019 Dividend(%) 4160
Announcement Date 23-May-2019 Ex Dividend Date 23-May-2019 Dividend(%) 240
Announcement Date 21-May-2018 Ex Dividend Date 21-May-2018 Dividend(%) 150
Announcement Date 25-May-2017 Ex Dividend Date 25-May-2017 Dividend(%) 110
Announcement Date 22-Apr-2016 Ex Dividend Date 22-Apr-2016 Dividend(%) 75
Announcement Date 30-Mar-2015 Ex Dividend Date 30-Mar-2015 Dividend(%) 60
Announcement Date 10-Mar-2014 Ex Dividend Date 10-Mar-2014 Dividend(%) 85
Announcement Date 07-Mar-2013 Ex Dividend Date 07-Mar-2013 Dividend(%) 25
Announcement Date 22-Oct-2010 Ex Dividend Date 22-Oct-2010 Dividend(%) 950
Announcement Date 18-Mar-2010 Ex Dividend Date 18-Mar-2010 Dividend(%) 200
Announcement Date 06-Apr-2009 Ex Dividend Date 06-Apr-2009 Dividend(%) 175
Announcement Date 04-Apr-2008 Ex Dividend Date 04-Apr-2008 Dividend(%) 100
Announcement Date 21-Mar-2007 Ex Dividend Date 21-Mar-2007 Dividend(%) 100
Announcement Date 21-Mar-2007 Ex Dividend Date 21-Mar-2007 Dividend(%) 200
Bonus
No Bonus has been declared by PGHL
Splits
No Split has been declared by PGHL
Others
Rights No Rights has been declared by PGHL
Procter & Gamble Health Ltd Peer Comparison
Shows key financial metrics for the company and its peers
This section compares Procter & Gamble Health Ltd with leading peers in the banking sector based on key metrics such as market capitalization, 1-year return, P/E (TTM), and PB ratio. It helps investors evaluate Procter & Gamble Health Ltd's relative performance and valuation against major competitors.
Stock Name Alivus Life Sciences Ltd ₹903.85 (-0.66%) M. Cap (Cr) 110.89 1 Yr Return (%) -16.31% P/E (TTM) 20.91 PB Ratio 3.94
Stock Name Sanofi Consumer Healthcare India Ltd ₹4740.20 (-0.12%) M. Cap (Cr) 109.17 1 Yr Return (%) NaN% P/E (TTM) 50.10 PB Ratio 39.98
Stock Name Sanofi India Ltd ₹4512.80 (-1.23%) M. Cap (Cr) 103.93 1 Yr Return (%) -25.74% P/E (TTM) 29.17 PB Ratio 13.55
Stock Name Procter & Gamble Health Ltd ₹5830.50 (-1.28%) M. Cap (Cr) 96.78 1 Yr Return (%) +13.89% P/E (TTM) 31.55 PB Ratio 15.60
Stock Name Blue Jet Healthcare Ltd ₹555.25 (-3.94%) M. Cap (Cr) 96.32 1 Yr Return (%) +5.31% P/E (TTM) 27.33 PB Ratio 10.42
Stock Name Marksans Pharma Ltd ₹191.73 (-0.69%) M. Cap (Cr) 86.89 1 Yr Return (%) -37.98% P/E (TTM) 24.71 PB Ratio 3.81
Stock Name Jeena Sikho Lifecare Ltd ₹691.90 (-3.37%) M. Cap (Cr) 86.00 1 Yr Return (%) +79.10% P/E (TTM) 55.87 PB Ratio 31.50
Procter & Gamble Health Ltd Cash Flow
Cash flow data provides a view of how money is generated and spent by Procter & Gamble Health Ltd, across its operating activities, investing activities, and financing activities.
PARTICULARS Operating Activities Mar 2025 168.69 Jun 2024 0.00 Jun 2023 236.00 Jun 2022 169.52 Jun 2021 247.26
PARTICULARS Investing Activities Mar 2025 9.59 Jun 2024 0.00 Jun 2023 -21.50 Jun 2022 -25.54 Jun 2021 -32.27
PARTICULARS Financing Activities Mar 2025 -234.74 Jun 2024 0.00 Jun 2023 -98.48 Jun 2022 -288.63 Jun 2021 -386.63
PARTICULARS Net Cash Flow Mar 2025 -56.46 Jun 2024 0.00 Jun 2023 116.02 Jun 2022 -144.65 Jun 2021 -171.64
Procter & Gamble Health Ltd Shareholding Pattern
This shows the ownership breakdown of Procter & Gamble Health Ltd, highlighting participation from Foreign Institutional Investors (FII), Mutual Funds, Public, Other Institutions, and Promoters.
Promoter 51.82%
Public 27.05%
Other Institutions 3.34%
FII 7.24%
Mutual Funds 10.56%
About Procter & Gamble Health Ltd
Procter & Gamble Health Limited was erstwhile incorporated as E Merck (India) Limited in 1967. The Company's name was changed from E Merck (India) Limited to Merck Limited on March 27, 2002. Later, the name of the Company was changed to Procter & Gamble Health Limited on 6 May, 2019. The company was set up to take over the business of the Indian branch of Emeda Exports with all their assets and liabilities. The company is a 51% subsidiary of German firm Merck KGaA, is a leading player in vitamin formulations.Procter & Gamble Health Limited is an Indian-based company principally engaged in the business of manufacturing and marketing of pharmaceuticals and chemicals. The company is the supplier of Pharmaceutical Chemicals, Formulated Chemical Products, Chemicals, Industrial Chemicals, Chemicals, Pharmaceutical Industry, and Chemical Products. The company offers prescription drugs, biotechnology products, and consumer health products, including over-the-counter products. They also offer products for the treatment of cancer, neurodegenerative diseases, infertility, endocrine and metabolic disorders, cardiovascular diseases, and other conditions with unmet medical needs.The company operates in two business divisions, namely Pharmaceuticals and Chemicals. The Pharmaceuticals business comprises of Ethicals used in the treatment of Cardiovascular and Metabolic diseases & Vitamin-based formulations and Consumer Health Care Products. The Chemicals business comprises of Bulk Drugs and Pigments. Segment revenue relating to the Chemicals business consists of bulk drugs, pigments and active pharmaceutical ingredients.The company started their operations as a manufacturer of pharmaceutical specialties and over the years, they have diversified their product range to include basic drugs, fine and industrial chemicals, and diagnostics. In the year 1981, the company became a public limited company they were the first in the Merck group.In December 2000, the company acquired the Livogen brand from Glaxo India for a consideration of Rs 8 crore. They entered into a co-marketing tie-up with the domestic Pharma Company Kopran for a new anti-inflammatory drug Rofecoxib, in the country. They launched new drug under the brand name of 'Acrobat', while Kopran launched the product under the brand name of 'Ziflam'. In the year 2002, the company launched Anti-diabetic molecule, namely 'Glimepiride' in the market. In the year 2004, the company sold their Taloja undertaking to Biochem Pharmaceutical Industries Ltd for a consideration of Rs 100 million. In addition, the Pharma section of the company started a new unit, namely Consumer Health Care to market medicines for common ailments. In the same year, the company formed a Public Charitable Trust known as 'Merck India Charitable Trust' with the main object of rendering financial assistance to children from the poorer section of society, to pursue primary and secondary education.In the year 2005, the company increased the production capacity of Bulk Drugs by 18 tonnes to 318 tonnes. They launched a new product, namely Pedimune, which is a formulation to improve the immunity level of Children.In the year 2006, the company expanded the production capacity of Bulk Drugs by 33 tonnes to 351 tonnes. In April 2006, the Life Science and Analytics (excluding Bulk Drugs) Business (LS&A business) of the Division was sold to Merck Specialities Pvt Ltd. All the assets and rights on the manufacturing and distribution facilities were transferred to Merck Specialities Pvt Ltd.In the year 2007, the company increased the production capacity of Injection/ Nasal Drops by 24 kilolitres to 427 kiloliters. The Pharmaceuticals segments launched Olmighty Tablets, Evion Forte Tablets, Polybion Complete Syrup, Met Neurobion Injection, Livogen CZ Tablets and Nasivion Care Drops.In the year 2008, the company expanded the production capacity of Bulk Drugs by 128 tonnes to 479 tonnes, Injection/ Nasal Drops by 13 kiloliters to 440 kiloliters and Tablets/ Capsules by 40 million Nos to 400 million Nos. In addition, they commissioned the project for the substantial expansion of the production capacity of their patented molecule, Oxynex ST. This plant is a 100% export-oriented unit and having a capacity to produce around 150 tonnes per year.In March 2016, the Health Ministry banned 344 fixed drug combinations through a gazette notification, based on the recommendation of its expert committee. Two drugs produced by the Company were impacted by this ban order. Pharmaceutical companies including the company challenged the order before the Hon'ble Delhi High Court and the Court was pleased to set aside the government notification. The Government may challenge the said decision of the Hon'ble Delhi High Court before Hon'ble Supreme court. Any adverse decision by the higher court or further addition to this list of banned drugs could impact the growth of the pharmaceutical companies. The Company has received a demand notice frorfi National Pharmaceutical Pricing Authority (NPPA) demanding a sum of Rs116.8 million plus interest Rs157.8 million alleging overcharging of price of the formulation Polybion L 100 ML syrup during the period from May 2006 to June 2009. The Company has challenged the said orders by way of a writ petition. In a separate proceedings filed by Cfadel Pharmaceuticals Private Limited, the manufacturer of the said drug, Hon'ble Kolkata High Court granted temporary stay against the demand notice subject to a sum of Rs22.5 million being deposited with NPPA, which the Company has made. The Company has been legally advised it has a good defendable case. The Company has challenged the said orders and will defend itself vigorously, however, any adverse orders by the courts may have material impact on the profits of the Company.During the year 2016, the Company introduced a new drug Lipigo (Rosuvastatin) which received enthusiatic market response.During the Financial Year 2018-19, Company launched Whisper Choice Aloe Vera.The Company launched flagship brand 'Neurobion Forte' in FY 2019-20. It launched the 'New Livogen Iron' and 'Multivitamin Tonic', a comprehensive iron syrup. Polybion launched the New Polybion Active Syrup, a superior B Complex Syrup enriched with Lysinein a sugar free tasty mango flavour base. During the year 2019-20, the shareholders of the Company vide their resolution dated June 12, 2018, had approved the execution of a business transfer agreement (BTA) with Merck Life Science Private Limited (MLSPL) to sell, lease or transfer certain businesses of the Company comprising biopharma, performance materials and life science segments (BPL business) to MLSPL , for an overall consideration of Rs 105,200 lakhs on a slump sale basis, which completed in November 30, 2018. And subsequent to this, Company's main business was changed to manufacturing and marketing of pharmaceuticals.In 2022-23, Company launched variants like Neurobion Alfa & Alfa D for patients with Diabetic Neuropathy.; launched Polybion A injection, a new and improved formulation.
Chairman & Independent Directo
S N Talwar
Registered office Godrej One 8th Floor, Projshanagar Vikhroli (East), Mumbai, Maharashtra, 400079
FAX :91-22-62109000
Background
Incorporation Year 1967
Face Value ₹10.00
Market Lot 1
FAQs on Procter & Gamble Health Ltd
How to buy Procter & Gamble Health Ltd shares on NSE?
To buy Procter & Gamble Health Ltd shares in Motilal Oswal, you just need to open a demat account and get your KYC documents verified.
What is the Procter & Gamble Health Ltd share price today?
The Procter & Gamble Health Ltd share price on NSE is ₹5830.50 today.
What is the market cap of Procter & Gamble Health Ltd on NSE?
The company has a market capitalization of ₹9678.27.
What is the PE & PB ratio of Procter & Gamble Health Ltd?
PE is 32 and PB is 185.
What is the 52 Week High and Low of Procter & Gamble Health Ltd shares?
Procter & Gamble Health Ltd stock price high: ₹6739 Procter & Gamble Health Ltd stock price low: ₹4903.85.